May 18, 2012
/PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that additional members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., for the company's AE37 breast cancer vaccine. The following distinguished scientists, scholars, and physicians join Dr.
Gabriel N. Hortobagyi
, MD, FACP (
University of Texas
MD Anderson Cancer Center), Dr.
Kathy D. Miller
, MD (
Indiana University School of Medicine
Melvin and Bren Simon Cancer Center), Dr.
Hope S. Rugo
, MD (
University of California San Francisco
(UCSF) Helen Diller Family Comprehensive Cancer Center), Dr.
Keith L. Knutson
, PhD (Mayo Clinic), and Dr.
James J. Mule
, MD (Moffitt Cancer Centre) on the SAB, the inaugural meeting of which is scheduled for
May 19, 2012
Dr. Ian Krop, MD, PhD
Dana-Farber Cancer Institute, Harvard Medical School
Dr. Krop received his MD and PhD degrees from the
Johns Hopkins School of Medicine
in 1996 and completed a residency in internal medicine at Johns Hopkins Hospital. After completing a medical oncology fellowship at the Dana-Farber Cancer Institute, he joined the faculty of the Women's Cancer Program at
Harvard Medical School
where he is now an Assistant Professor of Medicine and Director of Clinical Research for the Breast Oncology Center. His clinical and laboratory research focuses on developing novel molecularly targeted therapies for breast cancer treatment and on understanding and overcoming mechanisms of resistance to HER2-directed therapies. He has been a leader in the development of the antibody-drug conjugate trastuzumab-DM1 (T-DM1). He has led several biopsy intensive preoperative clinical trials of trastuzumab and bevacizumab based therapies with the goal of identifying resistance mechanisms and biomarkers of activity of these agents. His lab has also developed an optimized approach to collecting and molecularly characterizing circulating tumor cells and is using this method as an alternative strategy for identifying resistance mechanisms in the metastatic setting. He is co-chair of the HER2 working group of the Translational Breast Cancer Research Consortium and a member of the Susan G. Komen for the Cure Scientific Advisory Council.
Upon his appointment to the SAB, Dr. Krop commented: "The goal of my participation on the Antigen Express Scientific Advisory Board is to assist the company in optimizing a Phase III clinical development plan for AE37, a novel therapeutic approach to HER2 expressing breast cancer."